Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
2.600
+0.040 (1.56%)
Aug 22, 2025, 4:00 PM - Market closed
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 11 or 55.00% compared to the previous year.
Employees
31
Change (1Y)
11
Growth (1Y)
55.00%
Revenue / Employee
n/a
Profits / Employee
$472,355
Market Cap
155.69M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31 | 11 | 55.00% |
| Dec 31, 2023 | 20 | 3 | 17.65% |
| Dec 31, 2022 | 17 | 5 | 41.67% |
| Dec 31, 2021 | 12 | 2 | 20.00% |
| Dec 31, 2020 | 10 | 2 | 25.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ELDN News
- 10 days ago - Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 18 days ago - Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation - GlobeNewsWire
- 25 days ago - Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025 - GlobeNewsWire
- 5 weeks ago - Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025 - GlobeNewsWire
- 2 months ago - Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City - GlobeNewsWire
- 3 months ago - Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 3 months ago - Undercovered Dozen: Gevo, Eledon, Dorian, Iridium + - Seeking Alpha
- 4 months ago - Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet - Seeking Alpha